How comparative effectiveness research can help advance 'personalized medicine' in cancer treatment

doi:10.1377/hlthaff.2010.0637

. 2011 Dec;30(12):2259-68.

doi: 10.1377/hlthaff.2010.0637.

How comparative effectiveness research can help advance 'personalized medicine' in cancer treatment

Scott D Ramsey¹, David Veenstra, Sean R Tunis, Louis Garrison, John J Crowley, Laurence H Baker

Affiliations

PMID: 22147853
PMCID: PMC3477796
DOI: 10.1377/hlthaff.2010.0637

How comparative effectiveness research can help advance 'personalized medicine' in cancer treatment

Scott D Ramsey et al. Health Aff (Millwood). 2011 Dec.

. 2011 Dec;30(12):2259-68.

doi: 10.1377/hlthaff.2010.0637.

Authors

Scott D Ramsey¹, David Veenstra, Sean R Tunis, Louis Garrison, John J Crowley, Laurence H Baker

Affiliation

¹ Cancer Prevention Program, Fred Hutchinson Cancer Research Center, Seattle, Washington, USA. sramsey@fhcrc.org

PMID: 22147853
PMCID: PMC3477796
DOI: 10.1377/hlthaff.2010.0637

Abstract

The use of biomarkers to "personalize" cancer treatment--identifying discrete genes, proteins, or other indicators that can differentiate one type of cancer from another and enable the use of highly tailored therapies--offers tremendous potential for improved outcomes and lower treatment costs. However, the rapid development of cancer biomarker, or genomic, tests--combined with a paucity of evidence to support the effectiveness of the tests--presents a challenge for patients, clinicians, and other stakeholders. In this article we propose that comparative effectiveness research be used to strengthen what is now a haphazard process for developing and marketing cancer biomarker tests. We suggest novel funding approaches and a systematic process for moving from regulatory approval to the generation of evidence that meets the needs of stakeholders and, ultimately, patients.

PubMed Disclaimer

Cited by

Financing and Reimbursement Models for Personalised Medicine: A Systematic Review to Identify Current Models and Future Options.
Koleva-Kolarova R, Buchanan J, Vellekoop H, Huygens S, Versteegh M, Mölken MR, Szilberhorn L, Zelei T, Nagy B, Wordsworth S, Tsiachristas A; HEcoPerMed Consortium. Koleva-Kolarova R, et al. Appl Health Econ Health Policy. 2022 Jul;20(4):501-524. doi: 10.1007/s40258-021-00714-9. Epub 2022 Apr 4. Appl Health Econ Health Policy. 2022. PMID: 35368231 Free PMC article.
How Big Data, Comparative Effectiveness Research, and Rapid-Learning Health-Care Systems Can Transform Patient Care in Radiation Oncology.
Sanders JC, Showalter TN. Sanders JC, et al. Front Oncol. 2018 May 9;8:155. doi: 10.3389/fonc.2018.00155. eCollection 2018. Front Oncol. 2018. PMID: 29868477 Free PMC article.
Making genomic medicine evidence-based and patient-centered: a structured review and landscape analysis of comparative effectiveness research.
Phillips KA, Deverka PA, Sox HC, Khoury MJ, Sandy LG, Ginsburg GS, Tunis SR, Orlando LA, Douglas MP. Phillips KA, et al. Genet Med. 2017 Oct;19(10):1081-1091. doi: 10.1038/gim.2017.21. Epub 2017 Apr 13. Genet Med. 2017. PMID: 28406488 Free PMC article. Review.
Cost Implications of Value-Based Pricing for Companion Diagnostic Tests in Precision Medicine.
Zaric GS. Zaric GS. Pharmacoeconomics. 2016 Jul;34(7):635-44. doi: 10.1007/s40273-016-0388-x. Pharmacoeconomics. 2016. PMID: 26899833
Prospective molecular profiling of canine cancers provides a clinically relevant comparative model for evaluating personalized medicine (PMed) trials.
Paoloni M, Webb C, Mazcko C, Cherba D, Hendricks W, Lana S, Ehrhart EJ, Charles B, Fehling H, Kumar L, Vail D, Henson M, Childress M, Kitchell B, Kingsley C, Kim S, Neff M, Davis B, Khanna C, Trent J. Paoloni M, et al. PLoS One. 2014 Mar 17;9(3):e90028. doi: 10.1371/journal.pone.0090028. eCollection 2014. PLoS One. 2014. PMID: 24637659 Free PMC article.

See all "Cited by" articles

References

1. Ransohoff DF, Khoury MJ. Personal genomics: information can be harmful. Eur J Clin Invest. 2010;40(1):64–8. - PubMed
1. Center for Medical Technology Policy [home page on the Internet] Baltimore (MD): Center for Medical Technology Policy; [cited 2011 Aug 1]. Available from: http://cmtpnet.org/
1. SWOG [home page on the Internet] Ann Arbor (MI): SWOG; [cited 2011 Aug 5]. Available from: http://www.swog.org/
1. Evaluation of Genomic Applications in Practice and Prevention (EGAPP) [Internet] Atlanta, GA: Centers for Disease Control and Prevention; [updated 2011 Jul 29; cited 2011 Aug 5]. Available from: http://www.cdc.gov/genomics/gtesting/EGAPP/
1. Harris L, Fritsche H, Mennel R, Norton L, Ravdin P, Taube S, et al. American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer. J Clin Oncol. 2007;25(33):5287–312. - PubMed

Publication types

Actions
Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions

Grants and funding

LinkOut - more resources

Full Text Sources

[1] Ransohoff DF, Khoury MJ. Personal genomics: information can be harmful. Eur J Clin Invest. 2010;40(1):64–8. - PubMed

[2] Ransohoff DF, Khoury MJ. Personal genomics: information can be harmful. Eur J Clin Invest. 2010;40(1):64–8. - PubMed

[3] Center for Medical Technology Policy [home page on the Internet] Baltimore (MD): Center for Medical Technology Policy; [cited 2011 Aug 1]. Available from: http://cmtpnet.org/

[4] Center for Medical Technology Policy [home page on the Internet] Baltimore (MD): Center for Medical Technology Policy; [cited 2011 Aug 1]. Available from: http://cmtpnet.org/

[5] SWOG [home page on the Internet] Ann Arbor (MI): SWOG; [cited 2011 Aug 5]. Available from: http://www.swog.org/

[6] SWOG [home page on the Internet] Ann Arbor (MI): SWOG; [cited 2011 Aug 5]. Available from: http://www.swog.org/

[7] Evaluation of Genomic Applications in Practice and Prevention (EGAPP) [Internet] Atlanta, GA: Centers for Disease Control and Prevention; [updated 2011 Jul 29; cited 2011 Aug 5]. Available from: http://www.cdc.gov/genomics/gtesting/EGAPP/

[8] Evaluation of Genomic Applications in Practice and Prevention (EGAPP) [Internet] Atlanta, GA: Centers for Disease Control and Prevention; [updated 2011 Jul 29; cited 2011 Aug 5]. Available from: http://www.cdc.gov/genomics/gtesting/EGAPP/

[9] Harris L, Fritsche H, Mennel R, Norton L, Ravdin P, Taube S, et al. American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer. J Clin Oncol. 2007;25(33):5287–312. - PubMed

[10] Harris L, Fritsche H, Mennel R, Norton L, Ravdin P, Taube S, et al. American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer. J Clin Oncol. 2007;25(33):5287–312. - PubMed

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

How comparative effectiveness research can help advance 'personalized medicine' in cancer treatment

Affiliation

How comparative effectiveness research can help advance 'personalized medicine' in cancer treatment

Authors

Affiliation

Abstract

Similar articles

Cited by

References

Publication types

MeSH terms

Substances

Grants and funding

LinkOut - more resources

Full Text Sources

Abstract

Similar articles

Cited by

References

Publication types

MeSH terms

Substances

Related information

Grants and funding

LinkOut - more resources

Full Text Sources